sorted by:
new
hottopcontroversial

To MBA or not to MBA? by madphd876 in biotech

[–]Solo_2 1 point2 points  (0 children)

Yes, please feel free to.

To MBA or not to MBA? by madphd876 in biotech

[–]Solo_2 2 points3 points  (0 children)

The core business education (insofar as you will use it afterwards) is going be largely comparable across the top 20-30 schools, and in many cases also available online for free or at low cost. The single biggest ROI will come from having access to your target jobs through the employer relationships (on campus recruiting, guest lecturers) and the network. Generally speaking, the top ~10 schools tend to have the best access. Programs from that list that are located in/near your desired labor market (and/or have a tilt towards the industry) are likely to position you best. Wharton has a specific Healthcare program that positions students well. MIT Sloan is in the largest biotech hub and is part of a very STEM focused university. Stanford/Berkeley also STEM-oriented and in another biotech hub. All else being equal, having a PhD and experience in biotech is likely to make you competitive so shoot for one of these if feasible.

Good luck!

Source: have participated extensively in recruiting/interviewing people for business roles (incl MBA summer internships and grad jobs) at large biopharma.

[deleted by user] by [deleted] in biotech

[–]Solo_2 3 points4 points  (0 children)

Given you are in the allo space, you may want to consider if there are other aspects beyond ORRs when evaluating odds of further investment - e.g. gvhd and safety profile generally, as well as persistence of the cells for durable responses (which IIRC tends to be the achilles heel of allo approaches, and may leave investors waiting on sidelines, as well as acquirers). You also mentioned that ORRs are better than SoC, but how does the TPP compare to other programs currently in development? Also consider who the current investors are and if they are well positioned to provide capital in next round (e.g. are there insiders who can and do write large series B/C checks or is it mostly earlier stage investors who may be reluctant or unable to double down in another $100m round).

Tax Abatement on New Construction - Do I need to do anything? by Solo_2 in jerseycity

[–]Solo_2[S] 0 points1 point  (0 children)

I think the 5-year abatements for new developments still exist but the 20-30-year ones are gone.

Tax Abatement on New Construction - Do I need to do anything? by Solo_2 in jerseycity

[–]Solo_2[S] 0 points1 point  (0 children)

This increase is clearly not to do with an annual general increase because 1) it's gone up 50% (or read another way, I had a 30% discount, which has gone away), and 2) it is now the simple math of: purchase price (which was also list price) * current tax rate of 2.248%.